MCID: OVR059
MIFTS: 47

Ovary Adenocarcinoma

Categories: Reproductive diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma 12 15
Ovarian Adenocarcinoma 12 59 6 73
Adenocarcinoma of the Ovary 12
Adenocarcinoma of Ovary 59
Ovarian Adenoacanthoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3713
NCIt 50 C7700
Orphanet 59 ORPHA213504
ICD10 via Orphanet 34 C56
UMLS via Orphanet 74 C0948216
UMLS 73 C0948216

Summaries for Ovary Adenocarcinoma

Disease Ontology : 12 An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to ovary serous adenocarcinoma and adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Carboplatin and Nintedanib have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and placenta, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 ovary serous adenocarcinoma 30.9 CEACAM5 HRAS KRAS ZNF217
2 adenocarcinoma 29.9 ERBB2 HRAS KRAS TP53
3 hepatocellular carcinoma 27.4 BAX CEACAM5 HRAS KRAS KRT7 TP53
4 clear cell adenocarcinoma of the ovary 12.3
5 mucinous adenocarcinoma of ovary 12.1
6 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
7 uterine corpus serous adenocarcinoma 10.8 ERBB2 TP53
8 rare adenocarcinoma of the breast 10.7 KRAS TP53
9 oncocytic breast carcinoma 10.7 ERBB2 KRT7
10 female reproductive endometrioid cancer 10.7 KRT7 TP53
11 hyperplastic polyposis syndrome 10.7 KRAS TP53
12 eccrine sweat gland neoplasm 10.7 KRT7 TP53
13 non-proliferative fibrocystic change of the breast 10.7 ERBB2 TP53
14 uterine body mixed cancer 10.6 ARID1A ERBB2 TP53
15 schimmelpenning-feuerstein-mims syndrome 10.6 HRAS KRAS
16 periampullary adenoma 10.6 HRAS KRAS
17 apocrine adenocarcinoma 10.6 ERBB2 KRT7
18 paronychia 10.6 HRAS KRAS
19 oral cavity cancer 10.6 BAX ERBB2 TP53
20 small intestinal adenocarcinoma 10.6 BAX ERBB2 KRAS
21 mutyh-associated polyposis 10.6 KRAS TP53
22 spitz nevus 10.6 HRAS TP53
23 endometrioid ovary carcinoma 10.6 ARID1A POLE
24 ovarian benign neoplasm 10.6 KRT7 ZNF217
25 granulosa cell tumor of the ovary 10.5 ERBB2 KRT7 TP53
26 hidradenocarcinoma 10.5 ERBB2 KRT7 TP53
27 sweat gland cancer 10.5 ERBB2 KRT7 TP53
28 bladder carcinoma in situ 10.5 KRT7 TP53
29 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.5 ARID1A KRAS TP53
30 bile duct cysts 10.5 HRAS KRAS
31 barrett's adenocarcinoma 10.5 ERBB2 KRAS TP53
32 clear cell adenocarcinoma 10.5 ARID1A KRT7 TP53
33 cervical adenocarcinoma 10.5 ERBB2 KRT7 TP53
34 pleomorphic adenoma carcinoma 10.5 ERBB2 TP53
35 breast mucoepidermoid carcinoma 10.4 CEACAM5 ERBB2
36 pseudomyxoma peritonei 10.4 KRAS KRT7 TP53
37 serous cystadenocarcinoma 10.4 ERBB2 HRAS TP53
38 acneiform dermatitis 10.4 ERBB2 HRAS KRAS
39 intracystic papillary adenoma 10.4 CEACAM5 ERBB2
40 adenosquamous carcinoma 10.4 KRAS KRT7 TP53
41 adenosquamous cell lung carcinoma 10.4 ERBB2 HRAS KRAS
42 mucoepidermoid esophageal carcinoma 10.4 CEACAM5 TP53
43 epithelial-myoepithelial carcinoma 10.4 HRAS KRT7 TP53
44 exanthem 10.4 ERBB2 HRAS KRAS
45 cutaneous mucoepidermoid carcinoma 10.4 CEACAM5 KRT7
46 anal gland adenocarcinoma 10.4 CEACAM5 KRT7
47 intracranial chondrosarcoma 10.4 CEACAM5 TP53
48 anal canal adenocarcinoma 10.4 HRAS KRAS KRT7
49 liver angiosarcoma 10.4 HRAS KRAS TP53
50 ampulla of vater neoplasm 10.3 HRAS KRAS KRT7

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:



Diseases related to Ovary Adenocarcinoma

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.94 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.94 INHBA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.94 KRAS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.94 ZNF217
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.94 POLE
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.94 ZNF217
7 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.94 ZNF217
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.94 ZNF217
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.94 ZNF217
10 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.94 ZNF217
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 ERBB2 ZNF217
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.94 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.94 POLE ERBB2 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.94 ZNF217
16 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.94 INHBA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.94 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.94 POLE
19 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.94 POLE ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.94 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.94 ZNF217
22 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.94 POLE ERBB2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.94 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.94 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.94 POLE ERBB2 INHBA KRAS ZNF217
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.94 ZNF217
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.94 INHBA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.94 ZNF217
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.94 POLE ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.94 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.94 ZNF217
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 9.91 POLE
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.91 ZNF217
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.91 ERBB2 ZNF217
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 9.91 ZNF217
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.91 ZNF217
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.91 ZNF217
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.91 ZNF217
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.91 HRAS
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.91 ERBB2
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.91 HRAS
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.91 ZNF217
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.91 POLE ERBB2 HRAS ZNF217
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.91 POLE
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.91 HRAS

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 ERBB2 HRAS INHBA KRAS ACSBG1 TP53
2 neoplasm MP:0002006 9.7 ERBB2 HRAS KRAS POLE TP53 ARID1A
3 reproductive system MP:0005389 9.56 ERBB2 INHBA KRAS TP53 ACSBG1 ARID1A
4 skeleton MP:0005390 9.23 ERBB2 HRAS INHBA KRAS TP53 ARID1A

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
2
Nintedanib Approved Phase 2 656247-17-5 56843413
3
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
4
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
5
nivolumab Approved Phase 2 946414-94-4
6
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
7
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
8 Dianhydrogalactitol Investigational Phase 1, Phase 2 23261-20-3
9 Vaccines Phase 1, Phase 2,Phase 2
10 Albumin-Bound Paclitaxel Phase 2,Phase 1
11 Antimitotic Agents Phase 2,Phase 1
12 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
13 Angiogenesis Inhibitors Phase 2,Phase 1
14 Angiogenesis Modulating Agents Phase 2,Phase 1
15 Antibodies Phase 2
16 Immunoglobulins Phase 2
17 Pharmaceutical Solutions Phase 2
18 Antibodies, Monoclonal Phase 2
19 Alkylating Agents Phase 1, Phase 2
20 Antineoplastic Agents, Alkylating Phase 1, Phase 2
21 Anti-Bacterial Agents Phase 2
22 Antibiotics, Antitubercular Phase 2
23 Adjuvants, Immunologic Phase 2
24 Anti-HIV Agents Phase 2
25 Anti-Infective Agents Phase 2
26 Anti-Retroviral Agents Phase 2
27 Antiviral Agents Phase 2
28 Freund's Adjuvant Phase 2
29
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
30 CHI3L1 protein, human

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Completed NCT00243685 Phase 2, Phase 3
2 Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer Unknown status NCT00660101 Phase 1, Phase 2
3 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
4 Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients Completed NCT00127920 Phase 2 Avastin
5 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Recruiting NCT03365791 Phase 2
6 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
7 A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer Not yet recruiting NCT03281681 Phase 1, Phase 2 VAL-083, Dianhydrogalactitol
8 Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer Terminated NCT00091195 Phase 2 romidepsin
9 p53 Vaccine for Ovarian Cancer Terminated NCT00001827 Phase 2
10 Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Completed NCT02217956 Phase 1 Cisplatin;Bevacizumab
11 Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients Completed NCT00562003 Phase 1 Ad5-delta24RGD
12 Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Completed NCT02195973 Phase 1 LDE225
13 Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment Terminated NCT00585845 Phase 1
14 The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients Recruiting NCT03019315
15 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Ovary Adenocarcinoma

Genetic Tests for Ovary Adenocarcinoma

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

41
Ovary, Endothelial, Placenta, Thyroid, Liver, Colon

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 91)
# Title Authors Year
1
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( 29117515 )
2018
2
Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3. ( 28714011 )
2017
3
Sister Mary Joseph Nodule in an Ovary Adenocarcinoma. ( 28790552 )
2017
4
A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas. ( 26992853 )
2016
5
Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression. ( 25971681 )
2015
6
KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries. ( 25028599 )
2014
7
Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. ( 23707658 )
2013
8
What is your diagnosis? Ovarian adenocarcinoma. ( 24344516 )
2013
9
Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. ( 22826464 )
2012
10
Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma. ( 23056149 )
2012
11
CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma. ( 20571827 )
2011
12
Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. ( 20730571 )
2011
13
Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. ( 20514505 )
2010
14
Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. ( 20673788 )
2010
15
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. ( 20728204 )
2010
16
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. ( 19775429 )
2009
17
Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma. ( 19225795 )
2009
18
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. ( 19174584 )
2009
19
Dermatan sulfate domains defined by the novel antibody GD3A12, in normal tissues and ovarian adenocarcinomas. ( 19360434 )
2009
20
Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. ( 20044634 )
2009
21
[Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma]. ( 19090447 )
2009
22
Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. ( 19426511 )
2009
23
cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. ( 18554190 )
2008
24
CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. ( 18082618 )
2008
25
Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. ( 18097583 )
2008
26
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. ( 18709641 )
2008
27
Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. ( 17885491 )
2007
28
MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. ( 17713092 )
2007
29
Tight junction formation in epithelial ovarian adenocarcinoma. ( 17653889 )
2007
30
CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. ( 16942793 )
2007
31
Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report. ( 17977179 )
2007
32
Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma. ( 18041444 )
2007
33
Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. ( 17319785 )
2007
34
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. ( 17538174 )
2007
35
Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1. ( 17074516 )
2007
36
Carcinomatous lymphangitis as the initial manifestation of ovarian adenocarcinoma. ( 18026661 )
2007
37
Mucinous carcinoma of thyroid gland. Report of a primary and a metastatic mucinous tumour from ovarian adenocarcinoma with immunohistochemical study and review of literature. ( 17704943 )
2007
38
Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. ( 16897186 )
2006
39
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. ( 16996261 )
2006
40
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. ( 15870720 )
2005
41
Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. ( 15900302 )
2005
42
Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. ( 16203778 )
2005
43
Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. ( 15609323 )
2005
44
Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity. ( 15914035 )
2005
45
Role of estrogen and progesterone in the survival of ovarian tumors--a study of the human ovarian adenocarcinoma cell line OC-117-VGH. ( 16138714 )
2005
46
Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. ( 14766248 )
2004
47
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. ( 15492238 )
2004
48
Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma. ( 15581958 )
2004
49
[Relationship between expression of hyaluronan and pathologic features of ovarian adenocarcinoma]. ( 14960239 )
2004
50
Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. ( 12648589 )
2003

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
2 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh38 Chromosome 17, 39725125: 39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 118124 17 7571720 7590868 Mutation TP53 Ovarian adenocarcinomas

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 BAX ERBB2 HRAS KRAS TP53
2
Show member pathways
12.75 BAX ERBB2 HRAS KRAS TP53
3 12.72 BAX ERBB2 HRAS KRAS TP53
4
Show member pathways
12.65 BAX ERBB2 HRAS KRAS TP53
5
Show member pathways
12.58 BAX ERBB2 HRAS KRAS TP53
6
Show member pathways
12.51 ARID1A BAX ERBB2 HRAS KRAS TP53
7
Show member pathways
12.49 BAX HRAS KRAS TP53
8
Show member pathways
12.45 ERBB2 HRAS KRAS TP53
9
Show member pathways
12.43 BAX ERBB2 HRAS KRAS TP53
10 12.42 ERBB2 HRAS KRAS TP53
11
Show member pathways
12.4 ERBB2 HRAS KRAS TP53
12
Show member pathways
12.38 BAX ERBB2 HRAS KRAS
13
Show member pathways
12.37 ERBB2 HRAS KRAS TP53
14
Show member pathways
12.25 BAX ERBB2 HRAS KRAS TP53
15 12.21 BAX HRAS KRAS POLE TP53
16 12.17 ERBB2 HRAS KRAS TP53
17 12.16 BAX HRAS KRAS TP53
18
Show member pathways
12.01 BAX HRAS KRAS TP53
19
Show member pathways
11.99 BAX HRAS KRAS TP53
20
Show member pathways
11.94 BAX HRAS KRAS
21 11.91 HRAS KRAS TP53
22 11.88 HRAS KRAS TP53
23 11.87 BAX ERBB2 HRAS KRAS TP53
24
Show member pathways
11.86 ERBB2 HRAS KRAS
25 11.85 HRAS INHBA TP53
26 11.83 BAX HRAS KRAS TP53
27 11.81 BAX HRAS KRAS
28
Show member pathways
11.7 BAX HRAS KRAS
29 11.63 BAX ERBB2 TP53
30 11.56 HRAS KRAS TP53
31 11.46 ERBB2 HRAS KRAS
32 11.42 ERBB2 HRAS KRAS TP53
33 11.28 ARID1A ERBB2 HRAS TP53
34 11.23 HRAS KRAS TP53
35 11.13 ERBB2 HRAS KRAS
36 11.08 BAX ERBB2 HRAS KRAS TP53
37 11.07 ERBB2 HRAS KRAS TP53
38 10.74 HRAS KRAS

GO Terms for Ovary Adenocarcinoma

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.8 ARID1A BAX ERBB2 ESS2 INHBA
2 positive regulation of gene expression GO:0010628 9.55 ERBB2 HRAS INHBA KRAS TP53
3 Ras protein signal transduction GO:0007265 9.54 HRAS KRAS TP53
4 positive regulation of protein oligomerization GO:0032461 9.46 BAX TP53
5 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.43 BAX INHBA
6 positive regulation of MAP kinase activity GO:0043406 9.43 ERBB2 HRAS KRAS
7 response to isolation stress GO:0035900 9.32 HRAS KRAS
8 ERBB2 signaling pathway GO:0038128 9.13 ERBB2 HRAS KRAS
9 intrinsic apoptotic signaling pathway GO:0097193 8.8 BAX HRAS TP53

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 ACSBG1 ERBB2 HRAS KRAS POLE

Sources for Ovary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....